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Purpose and Methods: Optimization of remission-in-
duction and postremission therapy in elderly individuals
with acute myeloid leukemia (AML) was the subject of a
randomized study in patients older than 60 years. Remis-
sion-induction chemaotherapywas compared between dau-
nomycin (DNR) 30 mg/m 2 on days 1, 2, and 3 versus
mitoxantrone (MTZ) 8 mg/m 2 on days 1, 2, and 3, both
plus cytarabine (Am-C) 100 mg/m 2 on days 1 to 7. Follow-
ing complete remission (CR), patients received one addi-
tional cycle of DNR or MTZ chemotherapy and were then
eligible for a second randomization between eight cycles of
low-dose (LD)-Ara-C 10 mg/m 2 subcutaneously every 12
hours for 12 days every 6 weeks or no further treatment.
Results: A total of 242 patients was randomized to
DNR and 247 to MTZ. Median age of both study groups
was 68 years. Secondary AML was documented in 26%
and 25% of patients in either ann. The probability of
attaining CR was greater (P = .069) with MTZ (47%) than
with DNR (38%). Median duration of neutropenia was 19
(DNR) and 22 days (MTZ). The greater response rate to MTZ
therapy correlated with reduced occurrence of chemother-
apy resistance (32% v 47%, P = .001). With a median
follow-up of 6 years, 5-year disease-free survival (DFS) is
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8% in each arm. Overall survival estimates are not differ-
ent between the groups (6% v 9% at 5 yrs). Poor perfor-
mance status at diagnosis, high WBC count, older age,
secondary AML, and presence of cytogenetic abnormalities
all had an adverse impact on survival. SecondaryAML and
abnormal cytogenetics predicted for shorter duration of
CR. Among complete responders, 74 assessable patients
were assigned to Ara-C and 73 to no further therapy.
Actuarial DFS was significantly longer (P = .006) for Ara-C-
treated (13% [SE = 4.0%] at 5 years) versus nontreated
patients (7% [SE =3%]), but overall survival was similar (P =
.29): 18% (SE = 4.6%) versus 15% (SE = 4.3%). Meta-
analysis on the value of Ara-C postremission therapy con-
firms these results.
Conclusion: In previously untreated elderly patients
with AML, MTZ induction therapy produces a slightly better
CR rate than does a DNR-containing regimen, but it has no
significant effect on remission duration and survival. Ara-C
in maintenance may prolong DFS, but it did not improve
survival.
J Clin Oncol 16:872-881. o 1998 by American Society of
Clinical Oncology.
IN RECENT YEARS, there has been an intensified
interest in the development of treatment in the elderly
with acute myeloid leukemia (AML).1,2 The outcome of
these patients following remission-induction chemotherapy
has remained disappointing. While complete remission (CR)
rates in middle-aged adults have improved to values of 70%
to 80%. response rates in patients of aged 2 60 years
generally range between 40% and 50%. Overall survival at 2
years following start of treatment is often less than 20%. The
results of a palliative wait-and-see approach in patients older
than 65 years of age are worse than those of remission-
induction chemotherapy.3 Scarce studies have especially
dealt with the question of treatment development in the
elderly.3-9 An important question relates to the choice of drug
or the dose applied in remission-induction treatment. Usu-
Journal of Clinical Oncology, Vol 16, No 3 (March), 1998: pp 872-881
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ally, a combination of an anthracycline (eg, daunomycin
[DNR] or doxorubicin) and cytarabine (Ara-C) has been
applied. Variation of the dose of DNR has not brought any
significant benefit.5 In a noncontrolled study, mitoxantrone
(MTZ) plus Ara-C yielded promising CR rates of 58%.6 A
phase III study in adults of all ages that compared DNR plus
Ara-C versus MTZ plus Ara-C included 99 patients older
than 60 years of age. 10 In this cohort of patients, the MTZ
chemotherapy regimen was suggested to produce higher CR
rates (46% v 37%), but the numbers were small and the
results were based on a subgroup analysis. Therefore, the
question has remained as to whether MTZ would produce
greater response rates and also prolonged survival in elderly
patients with AML.
Another issue of the therapeutic management of elderly
AML concerns the employment of postremission treatment.
Should patients of higher age receive additional chemother-
apy once a CR has been obtained and, if so, what would be
the postremission therapy of choice? The application of
repeated cycles of high-dose Ara-C postremission showed
efficacy in reducing the recurrence of leukemia and improv-
ing survival in a large study of adults, but did not prove
successful in elderly patients." Conventional-dose (100
mg/m2/d), intermediate-dose (400 mg/m 2), and high-dose (3
g/m 2) schedules of Ara-C resulted in approximately equiva-
lent outcome in 60+-year-old patients." High-dose Ara-C
was associated with excessive toxicity in the elderly in the
latter study. The use of low-dose (LD)-Ara-C (10 mg/m 2/d)
has been favored for some time in the treatment of patients
with myelodysplastic syndromes and shown to offer active
antileukemic therapy.12-14 It has also been advocated in
elderly patients with AML, of whom a significant proportion
may have a hidden history of prior myelodysplasia (MDS).
LD-Ara-C as post-remission therapy has not been critically
evaluated yet.
We report here the results of a phase III study in which
MTZ induction therapy was compared with a schedule of
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DNR. Complete remitters were then eligible for a second
randomization and received LD-Ara-C for 12 days for eight
cycles as maintenance chemotherapy or no maintenance
chemotherapy.
MATERIALS AND METHODS
Study Design and Chemotherapy
In a collaborative phase III study of the European Organization for
the Research and Treatment on Cancer-Leukemia Cooperative Group
(EORTC-LCG) and the Dutch-Belgian Hemato-Oncology Cooperative
Group (HOVON), patients - 60 years of age were enrolled and
randomized to receive as induction therapy either DNR 30 mg/m2
by intravenous bolus on days 1, 2, and 3 plus Ara-C 100 mg/m2 by
continuous infusion on days 1 through 7, or MTZ 8 mg/m 2 by
intravenous bolus on days 1, 2, and 3 plus Ara-C 100 mg/m 2 by
continuous infusion on days 1 through 7 (Fig 1). The choice of these
dosages was based on a previous pilot study.3 In case of a partial
response (PR) to the latter induction cycle, patients were planned to
receive a second identical course of treatment. Complete responders
were to receive one cycle of consolidation therapy that consisted of the
same agents, but with 1 day of DNR or MTZ depending on the treatment
arm. The objective of the study was to compare DNR and MTZ
induction chemotherapy as regards the response rate, and in addition,
the duration of survival, disease-free survival (DFS), postchemotherapy
cytopenia, frequency of infectious complications, and number of days
spent in the hospital during and following induction chemotherapy.
Patients after consolidation and continuing in CR were eligible for a
second randomization between no further therapy (arm A) and LD-
Ara-C chemotherapy (arm B) (Fig 1). Arm B patients received
LD-Ara-C at 10 mg/m2 subcutaneously every 12 hours on days 1
through 12 at 42-day intervals for a total of eight cycles or until relapse.
The effects of LD-Ara-C maintenance chemotherapy on DFS and
overall survival were evaluated.
Eligibility
Patients > 61 years of age with AML were eligible if they had
MO-M7 AML according to the French-American-British (FAB) classifi-
cation. 15,16 Patients with secondary leukemias following MDS or
following chemotherapy for solid tumors or lymphomas more than 1
year before entry onto the study were also eligible. They were not
eligible if they had been treated with chemotherapy for AML or MDS.
They were also not eligible if they were refractory to platelet transfu-
DNR 30 mg/m2 day 1-3
N Ara-C 100 mg/m 2 continuous IV day 1-7
entry
cc
MTZ 8 mg/m2 day 1-3
Ara-C 100 mg/m2 continuous IV day 1-7




SC 12 hrs for 12 days
8x 6 wk cycles
Fig 1. Study scheme.
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sion; had severe hepatic (bilirubin level > three times normal value),
pulmonary, or renal disease (serum creatinine concentration > two
times normal value or creatinine clearance < 50 mL/min); or had
symptomatic heart disease that required therapy.
Criteria of Response and Evaluation of Outcome
CR was defined by a normocellular bone marrow that contained -5%
blast cells, including monocytoid cells, less than 10% blast cells and
promyelocytes, and less than 50% erythroid cells, no evidence of
extramedullary leukemia, and recovery of peripheral-blood values to
platelet counts of at least 100 X 109/L and neutrophils of at least 1.5 X
109/L. PR was defined by bone marrow smears that contained between
5.1% and 25% blasts and less than 5% circulating blast cells. Failure to
respond was classified as treatment resistance when there was no
reduction of the leukemic cell infiltration in the marrow or a reduction
that would not meet the criteria for a PR or CR. Hypoplasia followed by
leukemic regrowth was also classified as treatment failure. Regenera-
tion failure was defined as a prolonged hypoplasia of -8 weeks without
evidence of medullary leukemia. Early death was defined as death
before the completion of the induction cycle of therapy, and hypoplastic
death as death during the 4- to 5-week recovery interval after the
completion of chemotherapy. Survival duration and DFS were impor-
tant parameters of evaluation (defined later). Frequencies of excessive
toxicities, numbers of nights spent in hospital, frequencies of hemor-
rhages and infections, number of days to hematopoietic recovery, and
duration of fever were evaluated separately. Standard cytogenetic
techniques, including direct preparations, incubation of cultures for 24
or 48 hours, and banding techniques, were used at diagnosis to
karyotype the leukemia." Normal (NN) cytogenetics (this category
included the deletion of the Y chromosome), abnormal cytogenetics
(AA), and a mosaicism of abnormal and normal karyotypes (AN) were
recorded. Deletions of the long arm of chromosomes 5 and 7 (5q-, 7q-)
or the entire chromosomes (-5, -7), and abn 11q23, as well as +8
abnormalities, were regarded as poor-risk abnormalities, whereas
inv16(pl3q2 2), t(16;16)(p13q22), t(15;17)(q22;q21), and t(8;21) (q2 2;
q22) were considered as good-risk features. Karyotypic abnormalities
that involved three or more chromosomes but without any of the
aforementioned specific poor-risk or good-risk aberrations were classi-




The relationship between the initial categorized ordered variables
(WBC count, age, and performance status) and the CR rate after
induction was statistically tested using the X2 test for linear trend.2 1 For
unordered variables, the usual X2 test, with correction for continuity,
was used. The relationship between treatment randomized and response
(CR, resistance, or death during induction or during the hypoplastic
phase) was tested using Fisher's exact test. The 95% confidence interval
(CI) of the treatment difference was computed using the Confidence
Interval Analysis (CIA) program.22
Overall survival was calculated from the date of randomization until
the date of death, whatever the reason. DFS was calculated from the
date of first CR achieved after the induction course(s), until the date of
first relapse or date of death without confirmed relapse. For patients
randomized for the second question (Ara-C v no Ara-C), the starting
point for these analyses was the date of second randomization.
Actuarial curves were computed according to the Kaplan-Meier
technique. 2" The standard error was calculated according to the
Greenwood formula.2 1 The log-rank test was used to perform the
treatment comparison."2 The prognostic importance of different vari-
ables was assessed using the log-rank test (for binary variables) or the
log-rank test for linear trend21 (for ordered variables). The relative risk
(RR) of having an event per time unit in the MTZ treatment group
versus DNR group, along with its 95% CI, was computed using the odds
ratio technique. 22 The intention-to-treat principle was applied in the
statistical analyses.
The aim of the trial was to detect a difference in the CR rate from 40%
to 55% (using the usual X2 test, at = 0.05, / = 0.10) between the two
induction arms. The assumption was that such a difference in the CR
rate, if it truly existed, would lead to a difference in the survival at 3
years from 10% to 20%. Therefore, it was planned to enter 488 patients,
to evaluate their remission status after the induction course, and to
monitor them until relapse and death. The final analysis was planned to
be performed once 425 deaths had been reported within 3 years from
randomization (log-rank test, a = 0.05, P = 0.10).
To detect a 15% difference (10% v 25%) in DFS rates at 3 years
between the two maintenance groups (LD-Ara-C v no Ara-C), a total of
208 patients was required to be randomized. The final analysis was
planned once 171 events (relapses/deaths) had been reported (log-rank
test, at = 0.05, / = 0.10). As an insufficient number of patients were
randomized to address this question in the AML-9 trial (147 in total), 86
additional patients were randomized in the subsequent EORTC-
HOVON AML-I I trial in the elderly.2 3 Randomization was performed
centrally at the EORTC Data Center, based on the minimization
technique, with the stratification factors being patient age (60 to 70, 71
to 80, or >80 years) and treating center. For the second randomization,
LD-Ara-C versus no maintenance, first treatment allocated by random-
ization and treating center were used as stratification factors.
RESULTS
A total of 539 patients were registered between April 1986
and November 1993, of whom 270 individuals were random-
ized to induction therapy with DNR and 269 to treatment
with MTZ. Of these, four patients were considered to be
nonassessable because of incomplete data (n = 3), and in
one case, the dose of Ara-C administered was 10 times
greater than the protocol dose. Forty-six subjects were
ineligible, of whom 26 had been assigned to DNR and 20 to
MTZ treatment. Reasons for ineligibility were incomplete
data (n = 18), incorrect or inadequate diagnosis (n = 18),
insufficient organ function (n = 8), and exclusions (n = 2)
because of chemotherapy for AML or chemotherapy for
breast cancer during the year before registration. The clinical
and hematologic characteristics are listed in Table 1 for the
242 patients randomized to DNR treatment and the 247 to
MTZ treatment who could be evaluated, The median age of
the study population was 68 years (range, 60 to 88), of
whom only 5% were - 80 years. Less than 10% of patients
enrolled had a performance status that kept them in bed for
more than 50% of the time.
Response to Remission-Induction Chemotherapy
CR probabilities were 46.6% for patients on MTZ treat-
ment and 38.0% for patients on DNR (P = .067) (Table 2).
Interestingly, MTZ-treated patients showed a reduced prob-
ability of primary resistance to chemotherapy (47% v 32%,
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Table 1. Characteristics of Patients by Treatment Arm
% of Patients
DNR MTZ









In bed < 50% of time
In bed > 50% of time
Entirely disabled













Antecedent history (secondary AML)
Prior MDS












































Abbreviation: WHO, World Health Organization.
*Adequate cytogenetic examination was performed in 47.5% of patients
(n = 115) assigned to the DNR arm and 38.5% (n = 95) of the MTZ arm.
Percentage distributions of specific cytogenetic karyotypes are expressed
relative to the subgroup of patients (set at 100%) in whom adequate and
assessable chromosome analysis was performed.
P = .001) in the context of a slightly greater death rate (21%
v 15%) (Table 2).
Prognostic Factors for Response to
Remission-Induction Chemotherapy
Table 3 lists the factors at diagnosis that showed prognos-
tic value for CR. Age - 80 years, a progressively worse
performance status, and high WBC count (>25 X 10 9/L) all
predicted for a reduced CR probability. The unfavorable
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Table 2. Response to Induction Chemotherapy
DNR MTZ
(n = 242) (n = 247) Between
Response No. % No. % Groups (%) 95% CI Pt
CR 92 38.0 115 46.6 8.6 -0.2-17.3 .067
Resistance* 114 47.1 80 32.4 -14.7 -23.3--6.1 .001
Deatht 36 14.9 52 21.1 6.2 -0.6-13.0 .079
NOTE. 15 patients who did not receive any chemotherapy following
randomization because of early deteriorating condition (3 on DNR arm and 6
on MTZ arm) or subsequent refusal (one on DNR and 5 on MTZ) are included in
the analysis based on the intention-to-treat principle.
*Includes absolute resistance, PR (8% and 7%), and transient hypoplasia
followed by leukemic regrowth.
tincludes early death during chemotherapy (6% on both arms) and
postinduction death (9% and 15%).
+Fisher's exact test.
effect of age was associated with a reduced responsiveness
of the leukemia to chemotherapy (ie, resistance). In contrast,
poor performance status and (hyper)leukocytosis correlated
with a greater death rate (Table 4). Secondary leukemia
predicted for a greater probability of resistance to chemother-
apy (Table 4). Sex of the patient or FAB subtype of AML
Table 3. Analysis of Prognostic Factors for Response to
Induction Chemotherapy
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r t2 test for linear trend.
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Table 4. Prognostic Factors for Drug Resistance or Death Following
Induction Chemotherapy
Treatment Resistance Death
Factor % P % P
Age, years
< 70 39 17
70-79 38 .02* 19 .89*




In bed < 50% of time 36 .12* 28 < .00001*
In bed > 50% of time 25 .01t 47 < .000011t
Entirely disabled 40 40
WBC count (x 109/L)
< 25 37 14
25-99 48 .07* 20 .007*
> 100 34 .72t 30 .002t
Secondary AML
No 37 19
Yes 48 .03* 15 .45*
NOTE. P values according to the *x2 test or tx2 test for linear trend.
showed no predictive value for induction response, nor did
cytogenetics. However, of 489 patients, adequate cytoge-
netic examination was performed in only 210 (43%). Among
these, only 12 patients showed the favorable karyotypes
t(8;21) or abnl6(q22) or t(15;17), 42 had deletions of
chromosomes 5 or 7 (-5,5q-,-7,7q-), 25 presented with
1 1q23 or + 8 abnormalities, and seven other patients showed
complex chromosomal abnormalities. Because of the limited
numbers of the specific cytogenetic subgroups, most of the
subsequent analyses are based on the comparison of normal
(NN) versus abnormal (AN and AA) cytogenetics.
Toxicities Associated With MTZ Versus DNR
Remission-Induction Therapy
Since the great majority of patients (n = 489) received
induction cycle no. 1 and only 73 patients received cycle no.
2, the toxicities of DNR and MTZ chemotherapy were
directly compared after the first chemotherapy cycle. There
were no significant differences between the two treatment
groups as regards the frequencies of mild, gross, or debilitat-
ing hemorrhages (mean, 6% of cases); serious infections
(mean, 22%); liver function abnormalities (bilirubin level >
2.5 times normal; mean, 13%); renal toxicity (serum creati-
nine concentration > 2.5 times normal; mean, 4%); vomit-
ing and nausea, and severe intractable diarrhea (mean, 2%);
or severe oral toxicity that required liquid food intake or
parenteral nutrition (mean, 2%). The incidence of severe
infections among patients randomized to MTZ treatment
exceeded that in patients on DNR therapy: 25.1% versus
18.6% (P = .036). The duration of aplasia for patients who
achieved a CR was slightly longer (P = .06) for patients
randomized to the MTZ arm (median, 22 days) than for
those on the DNR arm (median, 19 days). Patients treated on
either arm had fever for a median of 6 days (P = .10). The
median number of days spent in the hospital was 31 days in
both the MTZ and DNR treatment groups (P = .71).
Survival and DFS
The median follow-up duration at the time of statistical
analysis was 6 years. The duration of survival was similar (P =
.23) in the two treatment groups (Fig 2), the RR of the death rate
per time unit of MTZ group versus DNR group was 0.893 (95%
CI, 0.742 to 1.076). Median survival estimates were 36 weeks
(DNR) and 39 weeks (MTZ). The percentages of patients still
alive at 5 years were 6% and 9%, respectively. For patients who
achieved CR after induction, the DFS probabilities between the
treatment arms were not different (Fig 3). The median DFS
estimates were 39 weeks in both groups. The DFS rate at 5 years
was 8%. Atotal of 174 patients (77 v 97) relapsed and 15 patients
died without relapse (seven v eight). The causes of death of the
latter patients in continuous CR were infection (n = 4), cardiac
arrest and myocardial infarction (n = 2), hemorrhage (n = 3),
and other or unknown cause (n = 6). The duration of survival
from CR was slightly longer (P = .29) in the MTZ arm. Median
survival estimates for complete responders were 74 weeks
(MTZ) versus 55 weeks (DNR), survival estimates at 5 years
were 12% versus 16%, and the RR was 0.85 (95% CI, 0.633 to
1.149).
The following initial factors appeared to relate to a shorter
duration of survival from start of treatment (Fig 4): older age
(P = .01), poor performance status (P < .001), high WBC
count (P < .001), secondary AML (P = .02) (data not
shown), and the presence of cytogenetic abnormalities (P =
.002). Interestingly, not only patients with a complete or
partial deletion of chromosomes 5 and 7 and complex
chromosome abnormalities had a poor prognosis, but also 12
(yers)
2 3
Number of patients at risk:
242 77 41 21
247 101 48 32
16 10 5 3 2 DNR
22 16 8 5 2 MTZ
Fig 2. Duration of survival according to induction Ireatment: DNR versus MTZ.
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1 2 3
Number of patients at rk:
92 30 13 10
115 47 22 13
7 5 3 3 2 DNR
11 6 3 L 0 MTZ
Fig 3. DFS from CR according to treatment: DNR versus MTZ.
patients who presented with good-risk cytogenetic features.
The Cox proportional hazards model showed that initial
performance status (P < .0001) and WBC count (P = .003)
were the two most important independent prognostic factors.
Secondary AML and abnormal cytogenetics predicted for





























36 6 18 9
16 12 8 4






Namebr of p me a*.k :
94 41 22 14
247 100 48 25
107 28 15 10
41 9 4 4
12 9 5 4 2
15 9 5 2 1
8 6 2 2 1
3 2 1 0 0
Numlxr ol paelms at risk
299 131 68 38
120 31 12 8
70 16 9 7
28 20 10 6 2 <2
7 4 3 2 2 <00
3 2 0 0 0 >-00
Number of apa at riL :
73 35 21 1 3
137 33 17 10
9 8 6 4 2 NN
8 5 2 t AN-AA
Fig 4. Duration of survival according to age (A), performance status (B), WBC count (C), and cytogenetic abnormalities (D).
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one versus two cycles of induction, or initial leukocytosis,
had no predictive value for DFS.
LD-Ara-C Versus No Maintenance Chemotherapy
Of the complete responders, 76 patients were randomized to
no further therapy (no Ara-C), and 75 patients to eight cycles of
LD-Ara-C. Four patients were ineligible because of no CR at the
time of second randomization, so that 73 (no Ara-C) and 74
(LD-Ara-C) patients could be evaluated. Comparative DFS and
overall survival are plotted in Fig 5, which shows an advantage
of DFS for patients assigned to LD-Ara-C maintenance therapy.
The RR estimate was 0.61 (95% CI, 0.43 to 0.87). The median
DFS duration following the second randomization was 29 weeks
for no-Ara-C and 51 weeks for LD-Ara-C treatment. At 3 years,
DFS was estimated at 7% (SE = 3.0%) for no maintenance and
20% (SE = 4.7%) for LD-Ara-C treatment; at 5 years, DFS was
estimated at 7% (SE = 3.0%) and 13% (SE = 4.0%), respec-
tively (P = .006). Four patients died without relapse: zero (no
Ara-C) versus four (LD-Ara-C). The median overall survival
estimates were 62 weeks (LD-Ara-C) versus 79 weeks (no
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5 4 2 2 2 1 NoAraC
14 14 6 2 2 I LD-Ar-C
C -
i-C .
Numbr of palienls at risk
73 38 24 t 16 10 4 •1 N A
74 53 28 23 16 0 2 2 I LD-Ara-C
Fig 5. Outcome according to treatment: no maintenance treatment (no
Ara-C) versus LD-Ara-C. (A) DFS and (B) overall survival.
LD-Ara-C therapy. Overall survival probabilities at 5 years were
18% (SE = 4.6%) in with LD-Ara-C and 15% (SE = 4.3%) for
no-Ara-C maintenance treatment (P = .29).
DISCUSSION
We present the results in 489 assessable patients of a
prospective randomized study that specifically deals with
treatment development in the elderly with AML. The results
of this study indicate that specific changes in the choice of
induction chemotherapy may affect the effect of treatment in
aged patients. They also show that LD-Ara-C maintenance
may modify DFS. The dependence of elderly patients on the
dose and the choice of the type of chemotherapeutic agents
in remission-induction therapy may differ from those in
younger adults with AML. In one study of patients - 60
years of age, DNR at a 30-mg/m2 dose (combined with
cytarabine) produced higher response rates than a regimen
with DNR 45 mg/m 2 or doxorubicin 30 mg/m 2.24 In contrast,
in patients younger than 60 years, the 45-mg/m 2 DNR dose
gave the best response results. In another study, DNR 50
4 ----
mg/m2 on day 1 only and DNR 60 mg/m 2 on days 1 to 3
produced differences, but the numbers of patients enrolled in
the latter study were small.5 MTZ has been evaluated in a
single-institution study, but induction with MTZ did not
result in a greater likelihood of response.6 A second study in
adults with AML that included a considerable number of
elderly patients had suggested better response probabilities
in case of MTZ induction therapy. 10 The results of the study
reported here indicate a slightly improved CR rate following
MTZ-based chemotherapy in comparison to DNR treatment,
probably due to a better antileukemic effect. The trial was
based on a comparatively large number of patients, the
patient characteristics in the treatment arms were extremely
well balanced, and the analysis showed an improvement of
response of approximately 10% (from 38% to 47%). Optimi-
zation of induction therapy specific for elderly patients
appears of considerable clinical relevance, since more than
50% of all newly diagnosed patients with AML are over 60
years of age. From the results of this study, it is also clear
that certain subgroups of patients are notoriously difficult to
induce into remission. Poor performance status at diagnosis,
high WBC count, and high age were all predictors of poor
response. A poor performance condition and high cell counts
mainly predicted for toxic deaths and high age and second-
ary leukemias mainly for resistance to therapy. In a prospec-
tive study of 104 patients, 6 secondary leukemia and high
blast counts were shown to be unfavorable predictors for
response, and in a retrospective study,25 high age and poor
performance status predicted remission failure. In our study,
patients > 80 years of age had a probability of attaining a
CR of 520%, and patients with a World Health Organization
(WHO) performance score - 3 had a CR rate of less than
30%. On the other hand, patients with hyperleukocytosis and
poor performance status showed greater frequencies of toxic
deaths and appeared more prone to early disease-related or
treatment-induced complications. Patients with secondary
leukemia presented more frequently with treatment refrac-
tory disease (Table 4). This was evident both from the failure
analysis of induction treatment and also the inferior DFS
results. Although the MTZ chemotherapy schedule provided
for better response rates, overall survival and DFS probabili-
ties did not improve. Why this effect did not translate into a
survival advantage remains unclear. One possible explana-
tion is that the quality of postremission treatment, which is
critical for maintaining the remission attained after induction
therapy, was inadequate.
A second question addressed in the study was concerned
with evaluating eight cycles of LD-Ara-C chemotherapy as
postremission therapy. At the time of initiation of the study,
'
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LD-Ara-C therapy was considered an attractive treatment
strategy in the elderly, because it had shown activity in
patients with MDS.12- 14 In fact, there may be a considerable
proportion of cases with an occult history of MDS among
elderly patients with AML. Further, it is of note that
high-dose Ara-C schedules, while showing improved activ-
ity in middle-aged adults with AML, have failed to produce
better outcome in patients 2 60 years."1 An attractive feature
of subcutaneous LD-Ara-C therapy is that it can be applied
to elderly individuals with limited toxicity and in an
outpatient context. The results of the study reported here
indicate better DFS for patients randomized to the Ara-C
schedule as compared with the group with no postremission
therapy. The DFS rate at 3 years of patients on Ara-C
maintenance therapy was almost threefold that of patients
without Ara-C therapy (20% v 7%; P = .006). The
advantage of LD-Ara-C therapy as regards DFS was ex-
pressed and maintained throughout an interval of 5 years at
least, even though the LD-Ara-C had been applied during 1
year only. In this respect, it is of note that the improved DFS
in LD-Ara-C patients in this study was obtained with
induction therapy that included a relatively moderate dose of
100 mg/m 2 Ara-C. It is conceivable that the quantitative
impact of LD-Ara-C 10 mg/m2 applied postremission for
preventing recurrence of AML may depend on the dosages
of Ara-C used in induction treatment and, for instance, the
effect of LD-Ara-C might be less apparent with more
intensive Ara-C induction schedules. In the subsequent
elderly AML study (EORTC-HOVON AML- 11) conducted
by our group,2 3 Ara-C in induction was applied at 200 mg/m2
(instead of 100 mg/m 2 for 7 days). However, in the latter
study, LD-Ara-C randomized according to exactly the same
schedule postremission had a moderate effect on remission
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duration and no effect on survival. 23 We performed a small
meta-analysis of these two EORTC-HOVON studies (AML-9
and AML-11). The meta-analysis provides an indication for
a positive effect of LD-Ara-C maintenance on DFS, but not
on overall survival (Table 5).
Still, little is known about the prognostic value of distinct
clinical and hematologic determinants, especially with respect to
outcome of AML in the elderly. This study in a large series of
previously untreated patients with AML of higher age has
matured to reach a median follow-up duration of 6 years and,
therefore, permits an analysis of prognostic factors for survival,
DFS, and relapse-free interval. High WBC count, poor perfor-
mance status, and, to a lesser extent, older age, prior hematologic
or oncologic disease (secondary AML), and presence of cytoge-
netic abnormalities, all independently predicted for poor sur-
vival. Although cytogenetic data were available in less than 50%
of patients and therefore the analysis of specific cytogenetic
features had a limited power, the presence of cytogenetic
abnormalities (AA and AN) was indicative of an inferior survival
prospect. Secondary AML and abnormal cytogenetics particu-
larly correlated with a higher rate of recurrence. Similarly, in a
comparatively small single-center study of 104 patients only, a
poor performance status (WHO grades 3 or 4), circulating
blasts Ž 0.2 X 109/L, and unfavorable cytogenetics were
associated with adverse survival.6 In another single-center study
of retrospective design, poor performance status and high age
were associated with shorter survival.25
We conclude that a combination of MTZ plus Ara-C
might enhance the CR rate in elderly patients with AML. In
addition, sequential cycles of LD-Ara-C at 10 mg/m2 show
clinically significant antileukemic activity when applied as
postremission therapy, especially following an induction
schedule that includes 7 days of 100 mg/m 2Ara-C.
Table 5. Meta-Analysis of the Effect of LD-Ara-C on DFS and Overall Survival in Elderly Patients With AML: Results From
EORTC-HOVON AML-9 and AML-11 Studies
Comparison for DFS Comparison for Overall Survival
No. of 0 0
Study Patients No. % RR 95% CI P" No. % RR 95% Cl P
AML-9
No-Ara-C 73 67 92 61 84
Ara-C 74 65 88 0.607 0.426-0.864 .006 64 86 0.827 0.580-1.178 .293
AML-1 1
No-Ara-C 44 35 80 29 66
Ara-C 42 32 76 0.830 0.513-1.344 .448 27 64 1.153 0.677-1.962 .600
Stratified by study
No-Ara-C 117 102 87 90 77
Ara-C 116 97 84 0.677 0.509-0.900 .007 91 78 0.912 0.682-1.230 .558
Abbreviations: O, observed number of events (relapse or death for DFS, death for survival); RR, relative risk.
*(Stratified) log-rank test.
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